Blepharospasm Clinical Trial
Official title:
Role of the Cortical Medial Frontal Areas in Blepharospasm
Verified date | April 14, 2009 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will examine the role of certain areas of the brain in blepharospasm, a type of
dystonia (abnormality of movement and muscle tone) that causes unwanted or uncontrollable
blinking or closing of the eyelids. The study will compare brain activity in healthy
volunteers and in people with blepharospasm to find differences in the brain that may lead to
better treatments for dystonia.
Healthy volunteers and people with blepharospasm who are 18 years of age and older may be
eligible for this study. All candidates are screened with a medical history. People with
blepharospasm also have a physical examination and blepharospasm rating.
Participants undergo transcranial magnetic stimulation (TMS) and electromyography (EMG) in
two 4-hour sessions, separated by 1 to 7 days.
TMS
A wire coil is held on the subject's scalp. A brief electrical current is passed through the
coil, creating a magnetic pulse that stimulates the brain. The subject hears a click and may
feel a pulling sensation on the skin under the coil. There may be a twitch in muscles of the
face, arm or leg. During the stimulation, subjects may be asked to tense certain muscles
slightly or perform other simple actions. Repetitive TMS involves repeated magnetic pulses
delivered in short bursts of impulses. Subjects receive 60 pulses per minute over 15 minutes.
EMG
Surface EMG is done during TMS to measure the electrical activity of muscles. For this test,
electrodes (small metal disks) are filled with a conductive gel and taped to the skin of the
face....
Status | Completed |
Enrollment | 72 |
Est. completion date | April 14, 2009 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
- INCLUSION CRITERIA: - Healthy volunteers (aged 18 or older) who are willing to participate. - Patients (aged 18 and older) with benign essential blepharospasm EXCLUSION CRITERIA FOR HEALTHY VOLUNTEERS: - Subjects with a history of neurological or psychiatric disorder, current use or a history of alcohol or drug abuse, psychiatric disorders requiring hospitalization or prolonged treatment, head injury with loss of consciousness, or epilepsy. - Subjects receiving drugs acting primarily on the central nervous system EXCLUSION CRITERIA FOR PATIENTS: - Subjects with a history of neurological disorders other than blepharospasm - Subjects with a history of a psychiatric disorder, current use or a history of alcohol or drug abuse, psychiatric disorders requiring hospitalization or prolonged treatment, head injury with loss of consciousness, or epilepsy. - Subjects receiving drugs acting primarily on the central nervous system - Subjects who have been treated with botulinum toxin injections within 3 months prior to their participation in the study - Subjects who are taking any medication for dystonia at the time of the study - Subjects with severe forceful closure of eyelids, subjects scoring more than 20 on the Blepharospasm Disability scale (Lindeboom et al., 1995). - Patients for whom participation in the study would, in the opinion of the investigators, cause undue stress or excessive apprehensiveness will also be excluded. The reason for that is that, in some patients, any stressful situation (like a medical exam or experiment) may cause a strong increase in the involuntary blink rate leading to a severe functional discomfort. The following exclusion criteria are due to the use of transcranial magnetic stimulation and repetitive transcranial magnetic stimulation up to 1Hz (Hallett 1999) for healthy volunteers and patients: - Subjects with cardiac pacemakers, intracardiac lines, implanted medication pumps. - Subjects with eye, blood vessel, cochlear, or eye implants. - Subjects with increased intracranial pressure as evaluated by clinical means - Subjects with metal in the cranium - Subjects with dental braces (but dental fillings are not a problem), metal fragments from occupational exposure or surgical clips in or near the brain. - Subjects with a personal or family history of hearing loss |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
Baker RS, Andersen AH, Morecraft RJ, Smith CD. A functional magnetic resonance imaging study in patients with benign essential blepharospasm. J Neuroophthalmol. 2003 Mar;23(1):11-5. — View Citation
Cunnington R, Iansek R, Thickbroom GW, Laing BA, Mastaglia FL, Bradshaw JL, Phillips JG. Effects of magnetic stimulation over supplementary motor area on movement in Parkinson's disease. Brain. 1996 Jun;119 ( Pt 3):815-22. — View Citation
Gerschlager W, Siebner HR, Rothwell JC. Decreased corticospinal excitability after subthreshold 1 Hz rTMS over lateral premotor cortex. Neurology. 2001 Aug 14;57(3):449-55. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01686061 -
Blepharospasm Patient Survey for Patients With Blepharospasm
|
||
Completed |
NCT00535938 -
MDs on Botox Utility (MOBILITY)
|
N/A | |
Recruiting |
NCT05027997 -
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
|
Phase 2 | |
Terminated |
NCT03263000 -
Photic Blink Reflex in People With Blepharospasm and Increased Blinking
|
||
Completed |
NCT03938363 -
Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia
|
N/A | |
Completed |
NCT02947815 -
Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm
|
Phase 2/Phase 3 | |
Completed |
NCT00406367 -
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm
|
Phase 3 | |
Completed |
NCT00682760 -
Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm
|
Phase 3 | |
Completed |
NCT00210431 -
Post Marketing Surveillance Study of Dysport
|
||
Completed |
NCT05103202 -
Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
|
||
Completed |
NCT04423341 -
Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm
|
Phase 2/Phase 3 | |
Completed |
NCT03269123 -
A Mechanical Device for Blepharospasm
|
N/A | |
Completed |
NCT00411255 -
Brain Stimulation to Treat Blepharospasm or Meige Syndrome
|
Phase 2 | |
Completed |
NCT00761592 -
Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm
|
Phase 4 | |
Completed |
NCT00001784 -
Mexiletine for the Treatment of Focal Dystonia
|
Phase 2 | |
Recruiting |
NCT04939909 -
Botulinum Toxin Relieves Anxiety, Depression and Sleep Disorderes in Patients With Blepharospasm
|
Early Phase 1 | |
Completed |
NCT03508882 -
Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm
|
Phase 4 | |
Completed |
NCT01814774 -
A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
|
N/A | |
Completed |
NCT00234507 -
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
|
Phase 2 | |
Recruiting |
NCT05618470 -
Wumeiwan Jiawei Fang Use in Patients With Blepharospasm
|
Phase 2/Phase 3 |